ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1708

The Efficacy and Safety of Piclidenoson vs Methotrexate in Early Rheumatoid Arthritis: Phase 3 Randomized, Double-blind, Placebo-controlled Study

Tatiana Reitblat1, Alexandra Gurman- Balbir2, Zivit Harpaz3, Motti Farbstein3, Michael Silverman3, William Kerns3 and Pnina Fishman3, 1Barzilai Medical Center, Ashkelon, Israel, 2Rambam Medical Center, Haifa, Israel, 3Can-Fite BioPharma, Petah Tikva, Israel

Meeting: ACR Convergence 2021

Keywords: clinical trial, drug, Randomized Trial, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Piclidenoson, a highly selective A3 adenosine receptor (A3AR) agonist, demonstrated safety and efficacy in phase 2 clinical studies in rheumatoid arthritis (RA) and psoriasis. Piclidenoson induces selective apoptosis of inflammatory cells via a molecular mechanism which entails de-regulation of the Wnt signaling pathway.

Methods: This randomized, double-blind, active- and placebo-controlled, parallel-group study enrolled patients with clinically active RA who were methotrexate (MTX)-naïve. Eligible patients were randomized to 4 groups in a 2:2:2:1 ratio: piclidenoson 1 mg; piclidenoson 2 mg; MTX; or matching placebo tablets/capsules. Piclidenoson or matching placebo tablets were administered every 12 h for up to 24 weeks of treatment. MTX or matching placebo capsules were administered once a week according to the dosing schedule. The primary endpoint was efficacy (noninferiority) of piclidenoson administered for 12 weeks relative to oral MTX, as assessed by the proportion of patients achieving a disease activity score (DAS) of low disease activity (LDA). Additional analyses of the primary efficacy parameter included comparison of each dose of piclidenoson to placebo at Week 12. Secondary endpoints included comparing response rates (ACR20, ACR50, and ACR70) between piclidenoson (each dose) and MTX or placebo. The study was designed to enroll 525 patients.

Results: Due to the SARS-CoV-2 pandemic, enrollment was paused and an interim analysis was performed after 50% of participants reached the Week 12 visit evaluation. The interim analysis included a total of 252 patients (72, 73, 73, and 34, in the piclidenoson 1 mg, piclidenoson 2 mg, MTX, and placebo groups, respectively). Patient demographics and baseline characteristics were overall similar between the groups. For the entire population included in the interim analysis, the median (range) age was 56 (18-75) years, and 197 (78%) were females. Piclidenoson was safe and very well tolerated. The proportion of patients experiencing any treatment emergent adverse events (TEAEs) were similar for all groups (17%, 25%, 26%, and 29%, respectively) and the majority of TEAEs were mild. Although piclidenoson efficacy was significantly superior to placebo, the study did not meet the primary endpoint which was noninferiority vs MTX (Figure). At 12 and 24 Weeks, ACR20, ACR50 and ACR70 response rates were overall similar between the piclidenoson 1 mg (which was more effective than the 2 mg dose) and the MTX groups. The clinical benefits of piclidenoson 1 mg (as reflected in the ACR50 and ACR70 response rates) seemed more pronounced after 24 weeks (Table).

Conclusion: Piclidenoson was safe, but did not meet the primary endpoint in the current study; although it was superior to placebo in the DAS-LDA analysis. Since the primary endpoint was not met, the trial was discontinued by the sponsoring company.

Figure.

Table.


Disclosures: T. Reitblat, None; A. Gurman- Balbir, None; Z. Harpaz, Can-Fite BioPharma, 3, 8; M. Farbstein, Can-Fite BioPharma, 3, 8; M. Silverman, Can-Fite BioPharma, 2; W. Kerns, Can-Fite BioPharma, 2, 11; P. Fishman, Can-Fite BioPharma, 3, 8.

To cite this abstract in AMA style:

Reitblat T, Gurman- Balbir A, Harpaz Z, Farbstein M, Silverman M, Kerns W, Fishman P. The Efficacy and Safety of Piclidenoson vs Methotrexate in Early Rheumatoid Arthritis: Phase 3 Randomized, Double-blind, Placebo-controlled Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-efficacy-and-safety-of-piclidenoson-vs-methotrexate-in-early-rheumatoid-arthritis-phase-3-randomized-double-blind-placebo-controlled-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-efficacy-and-safety-of-piclidenoson-vs-methotrexate-in-early-rheumatoid-arthritis-phase-3-randomized-double-blind-placebo-controlled-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology